IDO1 Inhibitor KHK2455

Drug Overview

IDO1 Inhibitor KHK2455, also known as HTX201, is an investigational oral Immunotherapy agent developed by Kyowa Kirin Pharmaceutical Development. It is designed to dismantle one of cancer’s most sophisticated defense mechanisms — the ability to chemically suppress the immune system within the tumor environment, effectively hiding from the body’s own cancer-fighting cells.

KHK2455 is a novel oral IDO1 inhibitor developed by Kyowa Kirin. It selectively inhibits the inactive apoenzyme form of IDO1, providing longer and more potent activity compared to inhibitors that bind only to the active holoenzyme. This novel mechanism of action sets KHK2455 apart from earlier IDO1 inhibitors and has positioned it as one of the most scientifically advanced agents in this class currently in clinical development.

• Name: IDO1 Inhibitor KHK2455 (also known as HTX201)
• US Brand Name: None assigned — currently investigational
• Drug Class: Selective IDO1 (Indoleamine 2,3-Dioxygenase 1) Inhibitor / Immunotherapy
• Route of Administration: Oral (tablet, taken by mouth)
• FDA Approval Status: Not FDA-approved. KHK2455 is currently being assessed in two phase I clinical trials: NCT02867007 in combination with mogamulizumab for advanced solid tumors, and NCT03915405 in combination with avelumab in adult patients with urothelial carcinoma.

What Is It and How Does It Work? (Mechanism of Action)

To understand KHK2455, it helps to know how tumors hide from the immune system. IDO1 is a heme-containing enzyme that degrades tryptophan (Trp) to kynurenine (Kyn), which may suppress effector T cells and activate T-regulatory cells (Tregs), thus reducing antitumor immune responses. High IDO1 expression in tumors may create a barrier and prevent penetration of active effector T cells.

In simple terms: cancer cells hijack IDO1 to starve T-cells of tryptophan and flood the tumor environment with a toxic byproduct called kynurenine — creating an invisible chemical shield. KHK2455 dismantles this shield through a precise three-step mechanism:

Targeting the Apoenzyme — A Novel Approach: Most IDO1 inhibitors attack the active, fully assembled form of the IDO1 enzyme. KHK2455 selectively inhibits the inactive apoenzyme form of IDO1, providing longer and more potent activity compared to inhibitors that bind only to the active holoenzyme. By blocking IDO1 before it fully assembles, KHK2455 prevents the enzyme from ever becoming functional — a fundamentally more durable form of inhibition.

Restoring Tryptophan Levels: With IDO1 blocked, the cancer cell can no longer break down tryptophan inside the tumor microenvironment. Tryptophan levels rise, restoring the essential amino acid that T-cells need to remain active, proliferate, and mount a cancer-killing immune response.

Collapsing the Kynurenine Shield: IDO1 inhibition results in immune modulatory effects which are important in boosting anti-cancer immune responses. As kynurenine production drops, the immunosuppressive signal that activates Tregs and silences effector T-cells is removed — effectively turning a “cold” immune-excluded tumor into a “hot,” immune-infiltrated one susceptible to both the body’s natural defenses and combination immunotherapy agents.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Advanced or metastatic solid tumors — studied in combination with mogamulizumab (anti-CCR4 monoclonal antibody) in a phase I dose-escalation and expansion trial (NCT02867007)
• Advanced urothelial carcinoma (bladder cancer) — studied in combination with avelumab (anti-PD-L1 monoclonal antibody) in a phase I trial (NCT03915405)

Non-Oncological Uses:

• There are currently no non-oncological indications under investigation for KHK2455.

Dosage and Administration Protocols

Patients received oral KHK2455 at fixed doses of 0.3, 1, 3, 10, 30, and 100 mg once daily as run-in monotherapy for 28 days (cycle 0), then in combination with 1 mg/kg intravenous mogamulizumab given weekly for cycle 1 and every 2 weeks from cycle 2 onward. No formal recommended phase II dose has been defined across all tumor types.Here is the Idelimenib (formerly known as KY1044) clinical protocol specification organized into a copyable tabular format. This agent is a first-in-class, fully human monoclonal antibody designed to selectively deplete intratumoral Regulatory T cells (Tregs) while stimulating effector T cells.

Idelimenib (ICOS Antagonist) Clinical Protocol Specification

Clinical Efficacy and Research Results

KHK2455’s clinical data comes from its first-in-human phase I program, with the most comprehensive published results emerging from the NCT02867007 trial reported in Cancer (Wiley) in 2025.

Overall, KHK2455 plus mogamulizumab was well tolerated with manageable adverse events at all doses. KHK2455 plus mogamulizumab demonstrated dose-dependent plasma concentration increases and suppression of IDO1 activity. One patient with advanced bevacizumab-resistant glioblastoma demonstrated a durable confirmed RECIST partial response, and nine patients achieved durable disease stabilization of ≥6 months.

The plasmatic kynurenine concentration reduced by 70.5% at the 100 mg dose, and >95% inhibition in kynurenine production was observed at ≥10 mg KHK2455. Six patients achieved durable RECIST disease stabilization for over 6 months, one of whom lasted ≥2 years. The median overall survival was 13.4 months and 30% of individuals survived for ≥2 years.

Pharmacokinetic-pharmacodynamic modeling presented at the 2021 AACR Annual Meeting confirmed that steady-state simulations showed that, when compared to baseline, the kynurenine-to-tryptophan ratio decreased with increasing KHK2455 dose and reached a constant nadir at the 100 mg dose — establishing a clear dose-response relationship that will guide future combination trial designs.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for KHK2455, as it is not FDA-approved. The phase I program established a generally manageable and tolerable safety profile.

Common Side Effects (>10%):

• The most common treatment-emergent adverse events (>30%) were drug eruption, nausea, infusion-related reaction (mogamulizumab component), fatigue, headache, and vomiting. Most events were grade 1–2 and did not require permanent discontinuation.
• Drug Eruption / Skin Rash — most frequently reported; typically managed with topical corticosteroids
• Fatigue and Headache — mild and consistent with other oral immunotherapy agents in this class

Serious Adverse Events:

• Grade 3 Gastrointestinal Necrosis: One patient with an initial diagnosis of lower esophageal cancer in the 100 mg cohort experienced grade 3 gastrointestinal necrosis and did not receive mogamulizumab. This was the only dose-limiting toxicity observed across the entire dose-escalation program.
• Immune-Mediated Reactions: As with all immunotherapy agents, immune-mediated adverse events may occur; monitor for signs of colitis, hepatitis, and endocrinopathy throughout treatment
• Infusion-Related Reactions: Attributed primarily to the mogamulizumab combination partner; premedication with antihistamines is recommended

Management Strategies:

• For skin rash: apply topical corticosteroids; escalate to oral steroids if Grade 2 or higher persists
• For gastrointestinal toxicity: hold treatment immediately; perform urgent endoscopic evaluation; initiate IV corticosteroids for confirmed immune-mediated colitis
• For fatigue: supportive care; rule out underlying infection or anemia

Research Areas

KHK2455 sits at a critical juncture in the evolving landscape of IDO1 inhibitor research. Despite promising results in early-phase clinical trials, a phase III study of the IDO1-selective inhibitor epacadostat in combination with pembrolizumab showed no difference versus placebo in metastatic melanoma — leading to diminished interest in IDO1 inhibitors. However, other approaches to inhibit this pathway continue to be considered. KHK2455’s novel apoenzyme-binding mechanism directly addresses the theoretical limitations of earlier agents, and its combination with mogamulizumab — which depletes immunosuppressive CCR4+ Treg cells — represents a rationally designed dual-immunosuppression strategy. Current research is focused on identifying predictive biomarkers of response, particularly baseline IDO1 expression levels and tumor microenvironment T-cell infiltration status, to better select patients most likely to benefit from this approach.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel including liver function tests (LFTs)
• IDO1 expression profiling of tumor tissue where available — may serve as predictive biomarker
• Baseline skin assessment — given high rate of drug eruption
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Monitor LFTs and CBC before each treatment cycle throughout the trial
• Watch closely for any signs of gastrointestinal toxicity — abdominal pain or bloody stool must be evaluated urgently
• KHK2455 is accessible only through participation in an approved clinical trial

Do’s and Don’ts:

• DO take KHK2455 at the same time each day during the monotherapy run-in period
• DO report any new skin rash, abdominal pain, fever, or unusual fatigue to your care team immediately
• DO attend all scheduled pharmacokinetic blood sampling and safety monitoring visits
• DON’T take KHK2455 outside of a supervised clinical trial — it is not available for routine use
• DON’T become pregnant during treatment — the embryo-fetal risk of immune pathway modulation has not been fully characterized
• DON’T self-manage any adverse events without consulting your oncology team first

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. IDO1 Inhibitor KHK2455 is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.